The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist , https://socialdosa.com/story11676238/both-medications-and-nmn-a-triple-threat-approach-to-metabolic-health